Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 5.9% - Here's Why

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was down 5.9% during mid-day trading on Tuesday . The company traded as low as $9.02 and last traded at $9.10. Approximately 36,808 shares changed hands during trading, a decline of 49% from the average daily volume of 72,562 shares. The stock had previously closed at $9.67.

Wall Street Analysts Forecast Growth

LYEL has been the subject of several research analyst reports. HC Wainwright reaffirmed a "neutral" rating and issued a $10.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, June 24th. Wall Street Zen upgraded Lyell Immunopharma to a "hold" rating in a research report on Friday, June 6th.

Lyell Immunopharma Stock Down 2.9%

The company's 50 day moving average price is $9.30 and its two-hundred day moving average price is $10.55. The firm has a market cap of $136.84 million, a PE ratio of -0.37 and a beta of -0.24.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.80) by $0.20. The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 514,649.22% and a negative return on equity of 73.66%. On average, analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LYEL. Graham Capital Management L.P. purchased a new stake in shares of Lyell Immunopharma during the 4th quarter valued at $33,000. RPO LLC acquired a new position in shares of Lyell Immunopharma in the fourth quarter valued at about $42,000. Wells Fargo & Company MN raised its stake in shares of Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after purchasing an additional 20,542 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $64,000. Finally, AQR Capital Management LLC boosted its position in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock valued at $94,000 after buying an additional 154,327 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.